Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
2646 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-02-25 (openpr.com)
Alzheimer Drug Market to Witness Impressive Growth by 2032: Biogen, Eli Lilly, Roche, Eisai, Novartis
Press release - HTF Market Intelligence Consulting Private Limited - Alzheimer Drug Market to Witness Impressive Growth by 2032: Biogen, Eli Lilly, Roche, Eisai, Novartis - published on openPR.com
Read more
2025-02-03 (openpr.com)
Tardive Dyskinesia Treatment Market Report Analysis and Research Studies, Comprehensive Insights and Key Players - Pfizer Inc., Biogen, Novartis AG.
Press release - DataM Intelligence 4Market Research - Tardive Dyskinesia Treatment Market Report Analysis and Research Studies, Comprehensive Insights and Key Players - Pfizer Inc., Biogen, Novartis AG. - published on openPR.com
Read more
2025-01-16 (openpr.com)
Drugs for Central Nervous System Diseases Market Size, Future Trends And Forecast to 2033 Biogen, Alkermes, Astrazeneca, Pfizer
Press release - FUTURE MARKET REPORT - Drugs for Central Nervous System Diseases Market Size, Future Trends And Forecast to 2033 Biogen, Alkermes, Astrazeneca, Pfizer - published on openPR.com
Read more
2025-01-09 (mondaq.com)
Are Reference Product Sponsors Asserting More Patents In BPCIA Litigation? - Patent - United States
On October 24, 2014, Amgen initiated the first litigation under the Biologics Price Competition and Innovation Act ("BPCIA"), asserting infringement of two patents.
Read more
2025-01-08 (openpr.com)
Tardive Dyskinesia Treatment Market | Trends, Growth & Key Therapies 2025 | Pfizer Inc., Biogen, Novartis AG
Press release - DataM Intelligence 4Market Research - Tardive Dyskinesia Treatment Market | Trends, Growth & Key Therapies 2025 | Pfizer Inc., Biogen, Novartis AG - published on openPR.com
Read more
2025-01-03 (openpr.com)
Orphan Drugs Market: Emerging Trends, Growth Drivers & Future Opportunities 2025- AstraZeneca., Incyte., Biogen., Novartis AG.
Press release - DataM Intelligence 4Market Research - Orphan Drugs Market: Emerging Trends, Growth Drivers & Future Opportunities 2025- AstraZeneca., Incyte., Biogen., Novartis AG. - published on openPR.com
Read more
2025-01-03 (openpr.com)
Erythromelalgia Treatment Market Is Booming Worldwide 2024-2031 | Teva Pharmaceutical Industries Ltd, Biogen, Pfizer Inc, Akorn, Novartis AG
Press release - Coherent Market Insights - Erythromelalgia Treatment Market Is Booming Worldwide 2024-2031 | Teva Pharmaceutical Industries Ltd, Biogen, Pfizer Inc, Akorn, Novartis AG - published on openPR.com
Read more
2024-12-31 (bigmoleculewatch.com)
Are Reference Product Sponsors Asserting More Patents in BPCIA Litigation? -
On October 24, 2014, Amgen initiated the first litigation under the Biologics Price Competition and Innovation Act (“BPCIA”), asserting infringement of two patents.
Read more
2024-12-18 (econotimes.com)
Eli Lilly’s Kisunla Approved in China, Paving the Way for Innovative Alzheimer’s Treatment Options -
China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The treatment, designed to slow memory decline and clear brain plaques, offers early-stage patients a unique...
Read more